HopeStage
Back to overview

Schizophrenia studies

Topics
More filters

Schizophrenia

Schizophrenia can affect how a person perceives reality, thinks and feels, sometimes involving hearing voices or holding unusual beliefs.

4505studies shown
Showing 1,285-1,296 of 4,505
Drug study icon
CompletedNCT06572449

Effectiveness of Slowly Increasing Dose and Food Effect of KarXT in schizophrenia

What is this study about?

Researchers studied KarXT, tracking side effects to assess safety in people with schizophrenia.

This study has finished and is no longer accepting participants.

Multiple locations, including Los Alamitos
SchizophreniaMedication studyAges 18–65
Countries
United States
Sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Drug study icon
CompletedNCT02411695

Safety study of Brexpiprazole (OPC- 34712) in schizophrenia

Official study title

A Phase 1, Multicenter, Open-label, Dose-Escalation Trial to Assess the Safety, Tolerability and Pharmacokinetics of Oral Brexpiprazole (OPC- 34712) in Adolescents With Schizophrenia

This study has finished and is no longer accepting participants.

Multiple locations, including Little Rock
SchizophreniaMedication studyAges 13–17
Countries
United States
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc. (Pharmaceutical company)
Drug study icon
CompletedNCT00690274

Study to Demonstrate Cognitive Enhancing Effects of BF2.649

Official study title

A Randomized, Double Blind, Placebo Controlled, Study to Demonstrate the Cognitive Enhancing Effects of BF2.649 in People With Schizophrenia and Schizoaffective Disorder

This study has finished and is no longer accepting participants.

In Dallas
SchizophreniaMedication studyAges 18–55
Countries
United States
Sponsor
University of Texas Southwestern Medical Center
Drug study icon
CompletedNCT03397134

Roluperidone for schizophrenia

What is this study about?

Researchers compared Roluperidone 64 mg, Roluperidone 32 mg and placebo to find out how the approaches affected psychotic symptoms in adults with schizophrenia.

This study has finished and is no longer accepting participants.

Multiple locations, including Rogers
SchizophreniaMedication studyAges 18–55
Countries
United States, Bulgaria, Poland, + 1 other
Sponsor
Minerva Neurosciences
Drug study icon
TerminatedNCT02261519

Safety & Efficacy of NaBen® for schizophrenia

What is this study about?

This study evaluates the safety and effectiveness of NaBen® for people with schizophrenia.

This study ended early.

In Pasadena
SchizophreniaMedication studyAges 18–45
Countries
United States
Sponsor
SyneuRx International (Taiwan) Corp
Drug study icon
CompletedNCT03160521

Risperidone for schizophrenia

What is this study about?

Researchers compared Risperidone ISM 75 mg, Risperidone ISM 100 mg and placebo to find out how the approaches affected psychotic symptoms in people with schizophrenia.

This study has finished and is no longer accepting participants.

Multiple locations, including Rogers
SchizophreniaMedication studyAges 18–65
Countries
United States, Ukraine
Sponsor
Rovi Pharmaceuticals Laboratories
Drug study icon
CompletedNCT03870880

Risperidone ISM® for schizophrenia

What is this study about?

Researchers compared Risperidone ISM 75 mg and Risperidone ISM 100 mg to find out how the approaches affected psychotic symptoms in people with schizophrenia.

This study has finished and is no longer accepting participants.

Multiple locations, including Rogers
SchizophreniaMedication studyAges 18–65
Countries
United States, Ukraine
Sponsor
Rovi Pharmaceuticals Laboratories
Drug study icon
TerminatedNCT05182476

Safety study of efficacy, Safety, and Tolerability of Luvadaxistat in schizophrenia

Official study title

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Subjects With Cognitive Impairment Associated With Schizophrenia, Followed by Open-Label Treatment

This study ended early.

Multiple locations, including Phoenix
SchizophreniaMedication studyAges 18–50
Countries
United States, Bulgaria, Czechia, + 2 others
Sponsor
Neurocrine Biosciences (Biotech company)
Drug study icon
TerminatedNCT05654870

Efficacy, Safety, and Tolerability of Valbenazine for schizophrenia

What is this study about?

This study evaluates the safety and effectiveness of Valbenazine for people with schizophrenia.

This study ended early.

Multiple locations, including San Jose
SchizophreniaMedication studyAges 13+
Countries
United States
Sponsor
Neurocrine Biosciences (Biotech company)
Drug study icon
CompletedNCT03201757

Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831

Official study title

A Phase 3 Study to Assess the Long Term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 in Subjects With Schizophrenia, Schizophreniform Disorder, or Bipolar I Disorder

This study has finished and is no longer accepting participants.

Multiple locations, including Little Rock
Schizophrenia, BipolarityMedication studyAges 16–70
Countries
United States, United Kingdom, Austria, + 9 others
Sponsor
Alkermes, Inc.

Registry coverage

We gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.